Literature DB >> 25336393

Alogliptin: concern about hepatotoxicity?

André J Scheen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25336393     DOI： 10.1007/s40262-014-0200-z

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  9 in total

1.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Hepatotoxicity of alogliptin.

Authors:  Elizabeth Barbehenn; Sammy Almashat; Michael Carome; Sidney Wolfe
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

Review 3.  Hepatotoxicity with thiazolidinediones: is it a class effect?

Authors:  A J Scheen
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 5.  Alogliptin: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

Review 6.  Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.

Authors:  K Gooßen; S Gräber
Journal:  Diabetes Obes Metab       Date:  2012-05-17       Impact factor: 6.577

Review 7.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

8.  A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.

Authors:  K Arnold Chan; Alison Truman; Jerry H Gurwitz; Judith S Hurley; Brian Martinson; Richard Platt; James E Everhart; Richard H Moseley; Norah Terrault; Lynn Ackerson; Joe V Selby
Journal:  Arch Intern Med       Date:  2003-03-24

Review 9.  Alogliptin benzoate for the treatment of type 2 diabetes.

Authors:  Yutaka Seino; Daisuke Yabe
Journal:  Expert Opin Pharmacother       Date:  2014-04       Impact factor: 3.889
  9 in total
  5 in total

1.  Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

2.  Author's reply to De Ponti et al.: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

Review 3.  Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  World J Hepatol       Date:  2015-07-08

Review 4.  Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Carolyn F Deacon
Journal:  Nat Rev Endocrinol       Date:  2020-09-14       Impact factor: 43.330

Review 5.  Alogliptin benzoate for management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  Vasc Health Risk Manag       Date:  2015-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.